Vamil Divan
Stock Analyst at Guggenheim
(4.48)
# 264
Out of 4,859 analysts
235
Total ratings
61.88%
Success rate
14.2%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintains: Buy | $9 → $8 | $2.20 | +263.64% | 1 | May 28, 2025 | |
| AMGN Amgen | Assumes: Neutral | $288 | $291.81 | -1.31% | 1 | May 20, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $86 | $62.74 | +37.08% | 11 | May 12, 2025 | |
| VALN Valneva SE | Maintains: Buy | $15 → $14 | $6.27 | +123.29% | 1 | May 8, 2025 | |
| ABBV AbbVie | Maintains: Buy | $214 → $216 | $191.50 | +12.79% | 26 | Apr 29, 2025 | |
| UNCY Unicycive Therapeutics | Initiates: Buy | $6 | $0.63 | +852.53% | 1 | Apr 21, 2025 | |
| MRK Merck & Co. | Reiterates: Buy | $115 | $80.32 | +43.18% | 14 | Apr 17, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Buy | $47 | $14.52 | +223.69% | 8 | Apr 14, 2025 | |
| JNJ Johnson & Johnson | Reiterates: Neutral | n/a | $155.26 | - | 15 | Apr 2, 2025 | |
| ASMB Assembly Biosciences | Initiates: Buy | $31 | $17.20 | +80.23% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.01 | +232.23% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $24.48 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $22.10 | +176.02% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $101 | $97.98 | +3.08% | 6 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $13.79 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.93 | +541.78% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $6.77 | +195.42% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.77 | +3,292.04% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.88 | +917.41% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.29 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $22.30 | -14.80% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $124.17 | -21.08% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $31.20 | +8.97% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.75 | +471.43% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $108.08 | -54.66% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $808.61 | -55.97% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $4.38 | +36.99% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $15.69 | +881.52% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $10.24 | +46.48% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.39 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $17.32 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $4.50 | +233.33% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $50.16 | +21.61% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $1.21 | +8,412.40% | 3 | Jan 17, 2018 |
Savara
May 28, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.20
Upside: +263.64%
Amgen
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $291.81
Upside: -1.31%
ANI Pharmaceuticals
May 12, 2025
Reiterates: Buy
Price Target: $86
Current: $62.74
Upside: +37.08%
Valneva SE
May 8, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $6.27
Upside: +123.29%
AbbVie
Apr 29, 2025
Maintains: Buy
Price Target: $214 → $216
Current: $191.50
Upside: +12.79%
Unicycive Therapeutics
Apr 21, 2025
Initiates: Buy
Price Target: $6
Current: $0.63
Upside: +852.53%
Merck & Co.
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $80.32
Upside: +43.18%
Travere Therapeutics
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $14.52
Upside: +223.69%
Johnson & Johnson
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $155.26
Upside: -
Assembly Biosciences
Mar 25, 2025
Initiates: Buy
Price Target: $31
Current: $17.20
Upside: +80.23%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $3.01
Upside: +232.23%
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $24.48
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $22.10
Upside: +176.02%
Feb 25, 2025
Reiterates: Buy
Price Target: $101
Current: $97.98
Upside: +3.08%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $13.79
Upside: -
Sep 10, 2024
Initiates: Buy
Price Target: $6
Current: $0.93
Upside: +541.78%
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $6.77
Upside: +195.42%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.77
Upside: +3,292.04%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $0.88
Upside: +917.41%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.29
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $22.30
Upside: -14.80%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $124.17
Upside: -21.08%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $31.20
Upside: +8.97%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.75
Upside: +471.43%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $108.08
Upside: -54.66%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $808.61
Upside: -55.97%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $4.38
Upside: +36.99%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $15.69
Upside: +881.52%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $10.24
Upside: +46.48%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $28.39
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $17.32
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $4.50
Upside: +233.33%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $50.16
Upside: +21.61%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $1.21
Upside: +8,412.40%